Currently there is one ongoing phase I trial to assess the immunogenicity, safety, tolerability and efficacy of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine [28] followed by a booster vaccination with a recombinant vaccinia expressing HPV-16/18 E6 and E7 (TA-HPV) [29] in combination with locally applied TLR7 agonist, imiquimod in patients with HPV-16+ high grade cervical intraepithelial neoplasia (CIN3) http://www.clinicaltrial.gov/ct2/show/NCT00788164. The gene discussed is TLR7; the disease is cervical intraepithelial neoplasia.